Chronic GVHD (cGVHD) has distinct clinical findings, which resemble features of autoimmune disease such as systemic sclerosis or Sjögren's syndrome involving exocrine glands 1,2 , and is believed to be distinct from the potentially lethal acute form of GVHD.
Chronic graft-versus-host disease (cGVHD) is a complication after minor
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This autoimmune phenotype has been attributed to donor-derived T cells that escape negative selection by the host thymus damaged by acute GVHD 3, 4 .
Bone marrow transplantation with 8 week-old donor B10.D2 (H-2d) mice and recipient BALB/c mice (H-2d) has been reported as a MHC-compatible, minor antigen (miHA)-incompatible model of cGVHD ( Supplementary Fig. 1a ) 5 . The phenotype of the mice closely resembles clinical samples of patients suffering from cGVHD ( Supplementary   Fig. 1b ). Signs of cGVHD appear by 3 weeks after BMT, and progresses to full-blown disease by 8 weeks characterized by low tear volume and excessive fibrosis of the lacrimal gland, conjunctiva, salivary gland, skin, lung, liver and intestine ( Supplementary Fig. 1c ).
Accumulation of donor-derived fibroblasts in fibrotic lesions surrounding exocrine ducts was observed ( Supplementary Fig. 1d ), which was similar to human patients as shown in our previous report 6 . These results suggested that donor-derived fibroblasts were part of the pathological process leading to cGVHD.
Multipotent mesenchymal stem/stromal cells (MSCs) in the bone marrow differentiate into several mesenchymal lineages such as fibroblasts, adipocytes, osteocytes and chondrocytes 7, 8 . However, the in vivo dynamics of MSCs after WBMT are still unknown due to the lack of specific markers. Furthermore, a crucial step involving in vitro expansion was required to isolate these cells, which may modify their phenotype and function 9 . 13 . In this study, we sought to answer the debated role of donor MSCs in the pathogenesis of the autoimmune-like phenotype of cGVHD using prospectively isolated MSCs and
HSCs in a mouse model of cGVHD.
RESULTS

Minor antigen mismatched HSC and MSC co-transplantation
In order to elucidate the role of donor-derived fibroblasts, we first established a modified cGVHD model by co-transplanting isolated hematopoietic stem cells (HSCs) and MSCs.
PαS-MSCs and side population (SP) HSCs ( Supplementary Fig 2a) from B10.D2 bone marrow were individually isolated by cell sorter and systemically co-transplanted into BALB/c mice (Fig. 1a) . Unlike the original WBMT model which co-transplanted splenic cells, the graft in our experiments does not include mature, differentiated cells both in the hematopoietic and non-hematopoietic fractions. In addition, there is lineage exclusivity, where all hematopoietic lineage cells are derived from SP-HSCs, while non-hematopoietic cells are of donor PαS-MSC origin 13, 14 . This modified co-transplantation model induced systemic fibrosis (Fig. 1b) , which was indistinguishable from that of cGVHD induced by the conventional WBMT model (Supplementary Fig 1c) . In addition, cells double positive for the fibroblast marker HSP47 and EGFP were detected in cGVHD tissue when EGFP + PαS-MSCs were transplanted with wild type B10.D2 SP cells (Fig. 1c, d ). Approximately 42.9 ± 7.3% of the HSP47 + fibroblasts in cGVHD tissue were GFP + , indicating that the majority of fibroblasts were derived from donor PαS-MSCs (Fig.1d) . On the other hand, a notable number of cells derived from mismatched donor SP-HSCs also migrated to fibrotic lesions, but none of the cells expressed HSP47 (Fig. 1c, e) . This shows that the donor fibroblasts originated from purified MSCs but not HSCs.
Mismatched PαS-MSCs induce cGVHD
In order to determine if either mismatched MSCs or HSCs play a dominant role in cGVHD, we performed the following transplantation. BALB/c mice were transplanted with a combination of BALB/c (syngeneic) HSCs and B10.D2 (mismatched) MSCs, or vice-versa (Fig. 2a) . Surprisingly, progressive fibrosis was observed in mice receiving mismatched
MSCs combined with syngeneic HSCs (Fig. 2b, Supplementary Fig. 2b, lower) . On the other hand, recipients of mismatched HSCs combined with syngeneic MSCs were either normal, or only suffered a forme-fruste form of the disease (Fig. 2b, Supplementary Fig. 2b , upper). Affected lesions in the mismatched MSC transplanted-mice had significantly higher HSP47 + fibroblasts (Fig. 2c, Supplementary Fig. 2c ) and lacrimal gland function was reduced as quantitated by tear volume (Fig. 2d) . The severity of cGVHD-associated fibrosis triggered by mismatched MSCs was dose dependent on the amount of transplanted MSCs (Fig. 2e) , which taken together, strongly suggest that the presence of mismatched
MSCs triggers the onset of cGVHD.
Deletion of PαS-MSCs prevents cGVHD
To confirm the requirement of mismatched MSCs for the onset of cGVHD, we tried removing PαS cells from donor bone marrow (MSC(-)) to see if this prevents the onset of cGVHD. As expected, MSC(-) mismatched WBM transplanted recipients showed minimal pathological changes ( Fig. 3a-b , Supplementary Fig. 3a ). HSP47 + fibroblasts associated with fibrotic lesions were also reduced ( Fig. 3c-d, Supplementary figure 3b ).
Mean tear secretion volume in mismatched WBM-transplanted mice gradually decreased reaching statistical significance at 8 weeks after transplantation, but was preserved in the MSC(-) group (Fig. 3e) . Therefore, the histological change and functional loss of the lacrimal gland was rescued by MSC depletion from donor cells, suggesting that mismatched MSCs alone can cause cGVHD.
Host T cells are required for the progression of cGVHD
The progression of cGVHD in this mouse model is T cell-dependent as shown by the lack of fibrotic lesions when BALB/c background nu/nu mice were used as recipients of mismatched B10.D2 MSCs ( Supplementary Fig. 4 ). The next question was to determine whether these pathogenic T cells were of donor origin, or residual host T cells that have lost 
Activated T-cells in mismatched MSC recipients
The fact that mature host T cells acquire the ability to react to auto-antigens during cGVHD is reminiscent of an autoimmune process, and therefore, 
Temporal increase of regulatory T-cells is suppressed with mismatched MSC
Increased IL-6 during an autoimmune process leads to the induction of Th17 cells and a decrease in regulatory T cells (Tregs) 16 . We therefore further examined whether similar events occur after mismatched MSCs transplantation. We found that CD4
Tregs in peripheral blood transiently increased following lethal irradiation and syngeneic transplantation of MSCs or WBMT which recovered to basal levels by 8 weeks (Fig. 5e, f ).
This transient increase in Tregs, reaching statistical significance at 3 weeks, was not observed after mismatched MSC or WBM transplantation (Fig. 5f ). This was followed by an increase of Th17 cells (Fig. 5g ) in both the mismatched WBMT and MSC groups reaching statistical significance compared to syngeneic controls at 3 weeks in the WBMT group (Fig 5h-left) , and 8 weeks in the MSC mismatch group (Fig 5h-right 
Detection of recipient-derived T cells in cGVHD patients
In human BMT patients, it is believed that host T cells are completely replaced by donor-derived T cells in the cGVHD phase 17 . However, our results using the cGVHD model mouse showed the role of recipient-derived T cells in the onset of cGVHD. In order to confirm if our findings also applied to human cGVHD cases, we performed FISH for X-and Y-chromosomes using peripheral blood mononuclear cell samples (PBMC) from cGVHD and non-cGVHD patients who received sex-mismatched WBM transplantation ( Table) . In accordance to our hypothesis, the frequency of recipient-derived CD3 + T cells was statistically higher in cGVHD patients compared to non-cGVHD patients (Fig. 6b ).
DISCUSSION
The therapeutic potential of MSCs was first reported in a case of acute GVHD transfused with haploidentical MSCs with dramatic improvement of symptoms 18 . This was followed by a phase II trial of MSC infusion for severe acute GVHD anticipating that allogeneic Therefore, it may include progeny of both stimulatory cells that interact with T cells and fibroblasts that directly contribute to tissue fibrosis. In order to clarify this point, further purification of MSCs will be necessary.
The clinical implications of our study cannot be ignored, for cGVHD is a major complication that can severely compromise quality of life in patients receiving bone marrow transplants. Our data clearly indicated that depletion of MSCs from donor tissue significantly reduced cGVHD-related fibrosis in all organs examined and rescued mice from lacrimal gland dysfunction associated with cGVHD. Targeted therapy against specific cytokines such as IL-6 was reported as a feasible therapy for preventing cGVHD 31 .
However, we have identified selective markers for isolating MSCs in humans (unpublished data). With the availability of markers to prospectively isolate human MSCs, excluding the MSC fraction from donor cells may be more effective in preventing the onset of cGVHD. A recent report also supports our hypothesis where the incidence of cGVHD is less following cord blood transplantation 32, 33 . Since we have found that MSCs are rarely detected in cord blood (unpublished data), this may explain the lower frequency of cGVHD in CBT. A prospective clinical study investigating the onset of cGVHD in association with the amount of MSCs that were included in the donor BM or cord blood will be necessary to confirm our hypothesis.
In conclusion, transplantation of minor antigen-mismatched MHC-compatible
MSCs interact with residual host T cells to induce the auto-immune phenotype observed in cGVHD, and strategic removal of these cells may be an effective way to prevent suffering due to cGVHD. 
Isolation of SP-HSCs
Bone marrow cells, suspended at 1x10 6 cells per milliliter in calcium-and magnesium-free
Hanks balanced salt solution (HBSS) supplemented with 2% fetal calf serum, 10 mM HEPES and 1% penicillin/streptomycin (HBSS+) were incubated with 5 μg /ml Hoechst 33342 (Sigma Aldrich) for 60 minutes at 37°C. The side population (SP) was sorted as described previously 34 . 
Isolation of CD45
MSCs and HSCs Co-transplantation
In all transplantation experiments, 1x10 4 PĮS-MSCs and 1x10 3 SP-HSCs ( Supplementary   Fig. 2a ) were intravenously injected into the tail vein of etherized recipient mice that had been lethally irradiated with a dose of 10.5 Gy (200 μl per mouse) as indicated in our previous studies 12, 34 .
T-cell isolation and co-culture with MSCs
Spleens were obtained from mice that received B10.D2 MSC or BALB/c MSC transplants. 
Proliferation assay
MSCs were plated at 1x10 4 cells/ well into 96-well plates in triplicate, which were irradiated at 52 Gy after adherence. 1x10 5 purified mouse T cells were added to each well.
On the fourth day, 5-bromo-2'-deoxyuridine (BrdU) was added. Twenty-four hours later, BrdU uptake was quantified 35 by cell proliferation enzyme-linked immunosorbent assay (ELISA) using a BrdU Kit (Roche Applied Science). The supernatant of the co-cultures was subjected to IL-6 ELISA using commercial kit (BD Biosciences). T cells and MSCs without irradiation after co-cultures were used for FACS analysis for analyzing the cellular source of IL-6 production.
Serum cytokine analysis
Serum was collected from mice using retro-orbital beads 31 . The concentration of IL-6 in the supernatants was determined by ELISA using a specific kit, according to the manufacturer's instructions (BD Biosciences). The experiments were performed in triplicate.
Flowcytometry analysis for intracellular cytokine IL-6 and IL-17
Two × 10 6 spleen cells were stimulated with 10 ng/mL phorbol myristate acetate (PMA) (Sigma) and 10 ng/mL inomycin (Sigma) in the presence of the Golgi inhibitor Brefeldin 
Foxp3 staining
Whole blood samples were co-stained with anti-CD4-FITC and anti-CD25-PE (PC61.5).
After fixation and permeabilization, cells were stained with APC-labeled anti-Foxp3 mAb (FJK-16s) (all mAbs were from e-Bioscience) as described 28 . Rat IgG2a, κ was used as an isotype control. 
CD3 immnunostaing and FISH for human
